IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of IMC-1C11. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of IMC-1C11. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of IMC-1C11. |
| Estrone | Estrone may increase the thrombogenic activities of IMC-1C11. |
| Estradiol | Estradiol may increase the thrombogenic activities of IMC-1C11. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of IMC-1C11. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of IMC-1C11. |
| Mestranol | Mestranol may increase the thrombogenic activities of IMC-1C11. |
| Estriol | Estriol may increase the thrombogenic activities of IMC-1C11. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of IMC-1C11. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of IMC-1C11. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of IMC-1C11. |
| Tibolone | Tibolone may increase the thrombogenic activities of IMC-1C11. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of IMC-1C11. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IMC-1C11. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of IMC-1C11. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of IMC-1C11. |
| Zeranol | Zeranol may increase the thrombogenic activities of IMC-1C11. |
| Equol | Equol may increase the thrombogenic activities of IMC-1C11. |
| Promestriene | Promestriene may increase the thrombogenic activities of IMC-1C11. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of IMC-1C11. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of IMC-1C11. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of IMC-1C11. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of IMC-1C11. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of IMC-1C11. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of IMC-1C11. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of IMC-1C11. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of IMC-1C11. |
| Formononetin | Formononetin may increase the thrombogenic activities of IMC-1C11. |
| Estetrol | Estetrol may increase the thrombogenic activities of IMC-1C11. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with IMC-1C11. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IMC-1C11. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with IMC-1C11. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with IMC-1C11. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with IMC-1C11. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IMC-1C11. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IMC-1C11. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with IMC-1C11. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with IMC-1C11. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with IMC-1C11. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with IMC-1C11. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with IMC-1C11. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IMC-1C11. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IMC-1C11. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with IMC-1C11. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IMC-1C11. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IMC-1C11. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with IMC-1C11. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IMC-1C11. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with IMC-1C11. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with IMC-1C11. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with IMC-1C11. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with IMC-1C11. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IMC-1C11. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with IMC-1C11. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with IMC-1C11. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with IMC-1C11. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with IMC-1C11. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with IMC-1C11. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with IMC-1C11. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with IMC-1C11. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with IMC-1C11. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with IMC-1C11. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with IMC-1C11. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with IMC-1C11. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with IMC-1C11. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with IMC-1C11. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with IMC-1C11. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with IMC-1C11. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with IMC-1C11. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with IMC-1C11. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with IMC-1C11. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with IMC-1C11. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with IMC-1C11. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with IMC-1C11. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with IMC-1C11. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with IMC-1C11. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with IMC-1C11. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with IMC-1C11. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with IMC-1C11. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with IMC-1C11. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with IMC-1C11. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with IMC-1C11. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with IMC-1C11. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with IMC-1C11. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with IMC-1C11. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with IMC-1C11. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with IMC-1C11. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with IMC-1C11. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with IMC-1C11. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with IMC-1C11. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with IMC-1C11. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with IMC-1C11. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with IMC-1C11. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with IMC-1C11. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with IMC-1C11. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Canakinumab. |